AEON Biopharma Provides Update on Development Pipeline

Core Viewpoint - AEON Biopharma is advancing its late-stage clinical pipeline for ABP-450, a proprietary botulinum toxin complex, despite mixed results in its chronic migraine program [1][2]. Clinical Pipeline Overview - The company has multiple late-stage programs aimed at demonstrating the safety and efficacy of ABP-450 for various medical conditions [2]. - The episodic migraine program has shown a favorable safety profile and achieved key secondary endpoints, although it did not meet the primary endpoint [3]. - Ongoing analysis of the chronic migraine Phase 2 study indicates that it did not achieve its primary or secondary endpoints [3]. - AEON is ready to initiate a Phase 3 study for cervical dystonia, having met significant endpoints in the Phase 2 study [3]. - A Phase 2 study for gastroparesis is ready to commence, with the IND already cleared by the FDA [3]. - IND-enabling studies for post-traumatic stress disorder (PTSD) are planned, with pilot data supporting the potential of ABP-450 for this indication [3]. Company Background - AEON Biopharma focuses on developing ABP-450 for debilitating medical conditions, particularly in the neurosciences market [4]. - ABP-450 is the same botulinum toxin complex marketed for cosmetic use under the name Jeuveau by Evolus [4]. - The company holds exclusive development and distribution rights for therapeutic indications of ABP-450 in several regions, including the U.S., Canada, and the EU [4].